Please login to the form below

Not currently logged in
Email:
Password:

Thermo Fisher

This page shows the latest Thermo Fisher news and features for those working in and with pharma, biotech and healthcare.

Allergan and Editas claim a CRISPR first in inherited blindness study

Allergan and Editas claim a CRISPR first in inherited blindness study

haemoglobinopathies. AstraZeneca is also making a play in the CRISPR field, with a collaboration on a CRISPR-focused research programme with the Wellcome Trust Sanger Institute, the Innovative Genomics Initiative, Thermo ... Fisher Scientific and the

Latest news

More from news
Approximately 2 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • AI: the smart money is on the smart thinking AI: the smart money is on the smart thinking

    Indeed, this has been evidenced recently by Thermo Fisher’s acquisition of Qiagen in May for $11.5bn.

  • A rising tide A rising tide

    This year satellite events were also held at inVentiv Health's London office, at Roche in Basel and at Thermo Fisher in Darmstadt, to which the New York ceremony was

  • Coming to an understanding Coming to an understanding

    thinking is increased,” says Dr Thomas Hein, president of EphMRA and global director customer insights and strategy immunodiagnostics at Thermo Fisher Scientific. ... Dr Hein has applied the practice at Thermo Fisher Scientific with in-house experts

  • Guiding decisions Guiding decisions

    is president of EphMRA and global director customer insights and strategy immunodiagnostics at Thermo Fisher Scientific.

  • Pharma deals during January 2015 Pharma deals during January 2015

    In a similar vein, other off the top 20 table deal activity of note was the announcement by AstraZeneca of four academic collaborations (Wellcome Trust, Innovative Genomics Institute, Thermo Fisher Scientific

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

  • Editas Medicine names James Mullen as chairman Editas Medicine names James Mullen as chairman

    Previously, Mullen has served as chief executive officer of Patheon, a pharmaceutical development and manufacturing services provider, until its acquisition by Thermo Fisher Scientific last year.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Could formulary intelligence be your brand differentiator?
Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
Lara Meyer
How COVID-19 is accelerating the threat of antimicrobial resistance
Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...
Improve clinical trials through patient journey mapping
Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...

Infographics